Market Overview

Vetr Issues Strong Buy As Cyberark Takes A Hit

Share:

The Vetr crowd on Monday upgraded its rating for Cyberark Software Ltd (NASDAQ: CYBR) from 4 stars (Buy), issued eight days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 85 percent of Vetr user ratings bullish.

Share price in Cyberark experienced a major correction at the start of Friday's session following a successful Q1 earnings report that saw the company exceed sales estimates by more than $1 million at $59.035 million for the quarter. The stock dropped more than 12 percent in response to the company's lowered Q2 guidance, finishing the day down about $6.85.

The stock picked up slightly the following Monday, but still traded down to close at $47.82.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Cyberark is up at $60.34, which is above the average analyst target price of $58.50. Less than 2 percent of Vetr users are holding CYBR in their watch lists.

Latest Ratings for CYBR

DateFirmActionFromTo
May 2019Initiates Coverage OnBuy
May 2019MaintainsOverweight
May 2019MaintainsBuy

View More Analyst Ratings for CYBR
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings Tech

 

Related Articles (CYBR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SLBMaintains41.0
BLKMaintains525.0
ALVMaintains70.0
AXPMaintains132.0
MANMaintains99.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Alan Knuckman's SunPower Trade

'Go Talk To Your Doctor': Citron's Andrew Left Vs. EXACT Sciences CEO Kevin Conroy